B. Boyett

发表

Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action

Margaret A. Madigan, K. Blum, D. Baron, 2019, Current Psychopharmacology.

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

B. Haight, M. Greenwald, S. Segal, 2019, The Lancet.

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)

K. Blum, D. Baron, M. Hauser, 2019, Journal of systems and integrative neuroscience.

Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.

William B. Downs, K. Blum, P. Thanos, 2019, Current pharmaceutical biotechnology.

Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

K. Blum, D. Baron, M. Gold, 2018, Journal of systems and integrative neuroscience.

Death by Opioids: Are there non-addictive scientific solutions?

K. Blum, R. Badgaiyan, D. Baron, 2019, Journal of systems and integrative neuroscience.

Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs)

K. Blum, D. Baron, M. Hauser, 2019, Journal of systems and integrative neuroscience.

In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.

K. Blum, T. Simpatico, R. Badgaiyan, 2020, Current psychopharmacology.

Opposing Roles of Peripherally-Derived γδ T Cells and Tregs in Epilepsy Pathogenesis

R. Badgaiyan, D. Baron, D. Siwicki, 2019 .

Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis

K. Blum, P. Thanos, T. Simpatico, 2020 .

Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis

K. Blum, J. Cadet, D. Baron, 2021, Frontiers in Psychiatry.

Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration.

K. Blum, R. Badgaiyan, D. Baron, 2020, Journal of systems and integrative neuroscience.

Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency

William B. Downs, K. Blum, P. Thanos, 2020, Journal of addiction science.

Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection

R. Dobbins, A. Heath, B. Boyett, 2022, The American journal of drug and alcohol abuse.

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.

L. Nelson, L. McLeod, W. Bickel, 2021, Drug and alcohol dependence.

Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.

K. Blum, R. Badgaiyan, D. Baron, 2020, Current psychopharmacology.